Loading
A blood test combining KRAS mutations with four proteins found 64% of 221 operable pancreatic cancers while wrongly flagging only one of 182 people without cancer.
Blood tests for KRAS gene mutations were combined with carefully thresholded protein biomarkers in 221 patients with resectable pancreatic ductal adenocarcinoma and 182 control patients without known cancer. KRAS mutations were detected in the plasma of 66 patients (30%), and every mutation found in plasma was identical to that subsequently found in the primary tumour (100% concordance). KRAS with four thresholded protein biomarkers increased sensitivity to 64%. Only one of the 182 control plasma samples was positive for any DNA or protein biomarker (99.5% specificity).
It quantifies how little DNA an operable pancreatic cancer sheds and why every serious early detection panel pairs DNA with proteins.
Shares Nickolas Papadopoulos, Bert Vogelstein, Proteomics & phosphoproteomics, Cell-free DNA (cfDNA).
Shares Nickolas Papadopoulos, Bert Vogelstein, Cell-free DNA (cfDNA), Multi-cancer early detection (MCED).
Shares Nickolas Papadopoulos, Bert Vogelstein, Cell-free DNA (cfDNA), Multi-cancer early detection (MCED).
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Resectable pancreatic ductal adenocarcinoma, Circulating tumour DNA (ctDNA), KRAS.
Shares Bert Vogelstein, Cell-free DNA (cfDNA), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Circulating tumour DNA (ctDNA).
Shares CA 19-9, Proteomics & phosphoproteomics, Cell-free DNA (cfDNA), Multi-cancer early detection (MCED).
Shares Cell-free DNA (cfDNA), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Resectable pancreatic ductal adenocarcinoma, Circulating tumour DNA (ctDNA).
Shares Cell-free DNA (cfDNA), Resectable pancreatic ductal adenocarcinoma, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).